(Boursier.com) — In large volumes, Abionyx Pharma soars 28.6% to 2.48 euros for its resumption of listings The next-generation biotechnology company is logically sought after after announcing that the pilot clinical trial phase 2a trial evaluating CER-001, the only naturally occurring recombinant apoA-I, as a treatment for septic patients at high risk of developing acute kidney injury (AKI) met both primary and secondary endpoints. There is no approved treatment for septic patients in the world.
Loreto Gesualdo, Full Professor, Head of the Nephrology, Dialysis and Transplantation Unit at the University of Bari Aldo Moro in Italy, and principal investigator of the RACERS study said: “There is a total lack of treatment for septic patients at high risk of developing acute kidney injury, a disease estimated to have caused 13.7 million deaths worldwide in 20191. Trial shows promising positive results across a variety of endpoints primary and secondary endpoints CER-001 was shown to be significantly able to scavenge endotoxins, modulate cytokine storm and provide endothelial protection The observed tendency to reduce both kidney damage and the need for organ replacement or length of stay in intensive care underscores the potential clinical significance of these findings.”
IT ICAP MIDACP notes that these final results of the study on the action of CER-001 in sepsis confirm the preliminary results, and suggest that the HDL molecule of Abionyx could offer a treatment solution for this indication and other acute inflammatory diseases… On the ‘purchase’ of the stock, the broker raised its target from 8 to 10.5 euros.
©2023 Boursier.com